📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

FOXO3a and the MAPK p38 are activated by cetuximab to induce cell death and inhibit cell proliferation and their expression predicts cetuximab efficacy in colorectal cancer. (2016)

First Author: Marzi L

Attributed to: Targeting the FOXM1 signature for early diagnosis and treatment in cholangiocarcinoma funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1038/bjc.2016.313

PubMed Identifier: 27685445

Publication URI: http://europepmc.org/abstract/MED/27685445

Type: Journal Article/Review

Volume: 115

Parent Publication: British journal of cancer

Issue: 10

ISSN: 0007-0920